Literature DB >> 6478405

Nuclear roundness factor. A predictor of progression in untreated Stage A2 prostate cancer.

J I Epstein, S J Berry, J C Eggleston.   

Abstract

A measurement of nuclear roundness involving computer-assisted image analysis of histologic specimens was used to predict the prognosis of 19 patients with Stage A2 prostate cancer. This technique accurately identified those tumors that clinically progressed without treatment and those that did not, in contrast to the Gleason grading system, which produced significant prognostic overlap. What separated most of these tumors was the quantification and degree of irregularity of a relatively small subpopulation of cancer nuclei among a majority of rounder nuclei. There are currently several practical limitations in the use of this method, but with improvements in technique and in methods of obtaining tissue, computerized image analysis of nuclear shape may become a valuable tool for analyzing prostate cancer in a quantitative manner, thereby providing valuable information relative to the prognosis of the individual patient.

Entities:  

Mesh:

Year:  1984        PMID: 6478405     DOI: 10.1002/1097-0142(19841015)54:8<1666::aid-cncr2820540830>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Nuclear envelope irregularity is induced by RET/PTC during interphase.

Authors:  Andrew H Fischer; Panya Taysavang; Sissy M Jhiang
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 2.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

3.  Periodicity of nuclear morphology in human fibroblasts.

Authors:  Laura Seaman; Walter Meixner; John Snyder; Indika Rajapakse
Journal:  Nucleus       Date:  2015       Impact factor: 4.197

4.  Morphometrically estimated variation in nuclear size. A useful tool in grading prostatic cancer.

Authors:  J H Blom; F J Ten Kate; F H Schroeder; R O van der Heul
Journal:  Urol Res       Date:  1990

5.  Evaluation of diagnostic efficiency of computerized image analysis based quantitative nuclear parameters in papillary and follicular thyroid tumors using paraffin-embedded tissue sections.

Authors:  N Gupta; C Sarkar; R Singh; A K Karak
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

6.  Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.

Authors:  James E Verdone; Princy Parsana; Robert W Veltri; Kenneth J Pienta
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

7.  Dysplasia discrimination in intestinal-type neoplasia of the esophagus and colon via digital image analysis.

Authors:  David R Martin; David R Braxton; Alton B Farris
Journal:  Virchows Arch       Date:  2016-08-05       Impact factor: 4.064

8.  Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.

Authors:  Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

9.  Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.

Authors:  Madeleine S Q Kortenhorst; Sumit Isharwal; Paul J van Diest; Wasim H Chowdhury; Cameron Marlow; Michael A Carducci; Ronald Rodriguez; Robert W Veltri
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

10.  DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.

Authors:  Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Journal:  Urology       Date:  2009-02-03       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.